1st Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Period 1st Quarter 2018 Filed Apr 19, 2018 Signed by Peter Norman

Official filing
Firm
ALKERMES, INC.
Client
ALKERMES, INC.
Income
—
Expenses
$1,000,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Maintain six protected classes for depression and schizophrenia under Medicare Part D

LobbyistCovered position, as disclosed
ABIGAIL PINKELE —

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Justice, Dept of (DOJ); Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Natl Drug Control Policy (NDCP); Veterans Affairs, Dept of (VA)

Pharmacy PHA

Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON Deputy Chief of Staff/Legislative Director for Congressman Brett Guthrie (KY-02)
PETER NORMAN —
ABIGAIL PINKELE Legislative Director for Rep. Gene Green from 2003-2012

Contacted: Justice, Dept of (DOJ); Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Natl Institutes of Health (NIH); Veterans Affairs, Dept of (VA)

Alcohol and Drug Abuse ALC

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act PL 115-141 Consolidated Appropriations Act of 2018 Ensure availability of all treatments for addiction through the Substance Abuse & Mental Health Services Administration. Advance use of addiction medicines in the Bureau of Prisons and within criminal justice funding (Byrne Jag)

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON Deputy Chief of Staff/Legislative Director for Congressman Brett Guthrie (KY-02)
PETER NORMAN —
ABIGAIL PINKELE Legislative Director for Rep. Gene Green from 2003-2012

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Executive Office of the President (EOP); Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; Justice, Dept of (DOJ)

Health Issues HCR

Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2456/HR 5311 - Comprehensive Addiction and Recovery 2.0 Act of 2018

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON Deputy Chief of Staff/Legislative Director for Congressman Brett Guthrie (KY-02)
PETER NORMAN —
ABIGAIL PINKELE Legislative Director for Rep. Gene Green from 2003-2012

Contacted: Justice, Dept of (DOJ); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); SENATE; Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); Natl Institutes of Health (NIH)

Bills named: H.R. 5327 (115th), H.R. 5311 (115th), S. 2456 (115th), S. 2589 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.